drotrecogin alfa

Drotrecogin alfa is a recombinant form of human activated protein C, developed using genetic engineering in a human cell line. It is a serine protease with anti-thrombotic, anti-inflammatory, and profibrinolytic properties. The drug acts by inhibiting coagulation factors Va and VIIIa to reduce thrombin formation (anticoagulant effect), inhibits plasminogen activator inhibitor-1 to promote fibrinolysis (profibrinolytic effect), and suppresses inflammatory responses by inhibiting tumor necrosis factor production and leukocyte adhesion. Drotrecogin alfa was primarily indicated for the treatment of severe sepsis with multiple organ failure but was withdrawn from the market after studies failed to show survival benefit[1][2][3][4][6].

Brand names

Xigris

Other names

recombinant activated protein Cactivated protein C (recombinant)drotrecogin alpha (activated)